Results 201 to 210 of about 102,706 (265)

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris   +5 more
wiley   +1 more source

B-Type Natriuretic Peptide as a Marker of Subclinical Heart Disease in a High-Burden Emergency Department Population With Sustained Asymptomatic Hypertension. [PDF]

open access: yesInt J Hypertens
Souffront K   +11 more
europepmc   +1 more source

Structural characterization of atrial natriuretic peptide amyloid fibrils from patients with atrial fibrillation. [PDF]

open access: yesNat Commun
Broggini L   +15 more
europepmc   +1 more source

Subclinical Primary Aldosteronism Is Characterized by Maladaptive Natriuretic Peptide and Adrenal Hormonal Physiology.

open access: yesJ Clin Endocrinol Metab
Parisien-La Salle S   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy